康柏西普辅助玻璃体切除术治疗增生型糖尿病视网膜病变

小班社会关于蔬菜教案(5篇) 小班社会关于蔬菜教案篇1一、目标：1、会用自己喜爱的颜色涂蔬菜。

2、熟悉蔬菜的名称。

3、喜爱和同伴依据蔬菜的颜色学习创编儿歌。

二、预备：1、西红柿小青菜、茄子、萝卜等实物。

2、油画棒未涂色的蔬菜图片若干张。

3、纸合一个。

三、过程：1、引起爱好，导入活动。

星期天，老师买了一些蔬菜来款待小4班的小伴侣人，这些蔬菜都藏在盒子里。

请小伴侣猜猜盒子里有哪些蔬菜？幼儿猜蔬菜的名称。

刚才小伴侣说了很多蔬菜的名称。

老师请小伴侣摸一摸盒子里究竟还有哪些蔬菜？2、幼儿感知蔬菜，并说出它们的颜色。

幼儿分别拿出蔬菜，说出蔬菜名称。

把这些蔬菜宝宝说给好伴侣听一听。

幼儿相互沟通。

老师带来了几种蔬菜宝宝？有四种蔬菜宝宝。

这四种蔬菜宝宝颜色一样吗？不一样。

幼儿分别说出蔬菜的颜色。

老师出示实物，请幼儿分别说出他们的颜色。

西红柿是红颜色,青菜是绿色。

茄子是紫色，萝卜是白色。

老师把这些蔬菜宝宝说一句好听的儿歌。

3、创编儿歌。

（1）、老师边编儿歌边出示图片。

西红柿红又红，茄子紫又紫。

（2）、请幼儿创编萝卜和青菜的儿歌。

萝卜白又白，青菜绿又绿。

（3）、集体朗诵儿歌一次。

（4）、请个别幼儿朗诵。

四、幼儿练习1、幼儿练习用自己喜爱的颜色给蔬菜宝宝穿衣服。

2、老师巡回指导小班社会关于蔬菜教案篇2活动目标：1、了解残留农药的危害，知道几种祛除农药的方法，懂得爱护自己的健康。

2、情愿通过自己的努力，想方法猎取学问。

3、喜爱与同伴合作，共同探究，共同共享。

活动预备：1、背景学问：了解有关残留农药的危害，并把握几种祛除方法。

2、物质材料：各种水果蔬菜、两块展板、幼儿手头资料。

3、活动铺垫：本活动重点让幼儿知道几种祛除农药的方法，所以把了解农药危害放在活动前的铺垫部分，请幼儿收集了农药危害的资料，大家一起展现沟通，知道残留农药会使人腹痛、腹泻、消化不良，引发心脑血管疾病，甚至危险生命等然后请幼儿回去后连续收集祛除农药的方法的`资料。

康柏西普预处理联合玻璃体切割术治疗增生型糖尿病视网膜病变尹妮;赵帅;朱红娜【期刊名称】《眼科新进展》【年(卷),期】2017(037)008【摘要】目的探讨抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物康柏西普对增生型糖尿病视网膜病变(proliferative diabetic retinopathy,PDR)患者玻璃体切割术(pars plana vitrectomy,PPV)术中和术后的影响.方法将2016年1月至12月于我科确诊PDR伴有玻璃体出血(vitreous hemorrhage,VH)和(或)牵拉性视网膜脱离(tractional retinal detach-ment,TRD)的123例149眼患者纳入研究,其中康柏西普组64例78眼,对照组59例71眼.康柏西普组于PPV术前3d玻璃体内注射抗VEGF药物0.50 mg(0.05 mL),对照组无处理.无明显并发症后2组行标准23G微创巩膜三通道玻璃体切割术,记录并分析手术时间、术中出血、医源性视网膜裂孔、眼内电凝使用、是否硅油填充等,对术前及术后1个月视力及黄斑厚度进行对比,观察术后并发症情况.结果两组患者年龄、性别、糖化血红蛋白、糖尿病病程,VH≥Ⅲ级眼数(56/78、45/71),术前TRD比较均无明显差异.康柏西普预处理可明显降低PPV术中出血(43/78、49/71)、医源性视网膜裂孔的概率(11/78、21/71),减少眼内电凝使用(57/78、62/71)及硅油填充(43/78、51/71),进而缩短手术时间(58.63±21.66)s、(72.69±22.48)s,且其可明显改善术后视力(0.23±0.15,0.16±0.11)及黄斑水肿厚度(260.95±27.44) μm、(330.81±36.62) μm,同时降低二次积血发生率(3/78、10/71).结论康柏西普预处理联合PPV是治疗PDR患者一项积极有效的治疗方案.%Objective To discussthe intraoperative and postoperative effects of conbercept combined with pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR) patients.Methods From January 2016 to December 2016,123 PDR patients (149 eyes) aged 41-65 years old with nonclearing vitreous hemorrhage (VH) and/or tractional retinal detachment (TRD) were enrolled in thisstudy.According to whether preoperative intravitreal injection conbercept,the patients were divided into two groups:Conbercept group (64 cases,78 eyes),Control group (59 cases,71 eyes).Conbercept group was treated with intravitreal injection of Conbercept 0.50 mg (0.05 mL) at 3 days before PPV.Then the standard 23G minimally invasive sclera three-channel vitrectomy was performed if no significant complications after the injection of conbercept.The operation time,intraoperativebleeding,iatrogenic retinal hole,use of endodiathermy and silicone oil,and postoperative complications were recorded and analyzed.The visual acuity and macuiar thickness were compared before and 1 month after the surgery.Results Two groups had no difference on age,sex,HbA1C,duration,VH ≥ three degree(56/78,45/71),TRD.Conbercept pretreatment could significantly reduce the bleeding during PPV (43/78,49/71),the probability of iatrogeuic retinal holes (11/78,21/71),reduce intraocular electrocoagulation using (57/78,62/71) and silicone oil (43/78,51/71),and then shorte n the operation time (58.63 ± 21.66)s and (72.69 ± 22.48)s,and it could significantly improve the postoperative visual acuity (0.23 ±0.15,0.16 ± 0.11) and macular edema thickness (260.95 ± 27.44) μm and (330.81 ± 36.62)μm,while reduce the incidence of sec ond bleeding(3/78,10/71).Conclusion Conbercept pre-treatment combined with PPV for PDR is a positive and effective treatment,which has good clinical application significance.【总页数】3页(P770-772)【作者】尹妮;赵帅;朱红娜【作者单位】710002陕西省西安市,西安市第一医院眼科;710002陕西省西安市,西安市第一医院眼科;710002陕西省西安市,西安市第一医院眼科【正文语种】中文【中图分类】R774【相关文献】1.不同波长激光光凝联合康柏西普治疗非增生型糖尿病视网膜病变的临床疗效对比分析 [J], 宾蓉;夏仁春2.23G玻璃体切割术前、术中辅助玻璃体内注射康柏西普治疗增生型糖尿病视网膜病变(PDR)的疗效分析 [J], 薛鹏程;游志鹏;付书华;彭灵;董乐3.术前及术中2次应用康柏西普辅助玻璃体切割术治疗增生型糖尿病视网膜病变的临床研究 [J], 梁泽玉;陈松;何广辉;王俊华;高翔;武斌4.激光光凝联合康柏西普治疗增生型糖尿病视网膜病变的效果 [J], 赵丽君;师学伟;张薇5.激光光凝联合康柏西普治疗增生型糖尿病视网膜病变的效果观察 [J], 李冰;杨宾;杨志理因版权原因，仅展示原文概要，查看原文内容请购买。

·17JOURNAL OF RARE AND UNCOMMON DISEASES, DEC. 2023,Vol.30, No.12, Total No.173【第一作者】昝晓宁，女，住院医师，主要研究方向：眼科。

E-mail：157****************【通讯作者】昝晓宁·论著·康柏西普联合微创玻璃体切割术对增殖型糖尿病视网膜病变患者视功能及疾病相关因子水平的影响*昝晓宁* 尚利晓 李 琰河南科技大学第一附属医院眼科 (河南 洛阳 471000)【摘要】目的 探讨接受微创玻璃体切割术的增殖型糖尿病视网膜病变患者联合康柏西普治疗后视功能与疾病相关因子水平的变化情况。

方法 此次研究所选病例数共98例，均为河南科技大学第一附属医院2020年10月至2022年12月所收治的增殖型糖尿病视网膜病变患者，将其纳入至研究后分成治疗方式为接受微创玻璃体切割术治疗的A组以及切割术联合康柏西普治疗的B组，例数相等，均为49例，患眼共98只，分组方式为随机数字表法。

两组患者均随访3个月。

比较两组患者治疗后的临床疗效，治疗前后视功能、血清血管内皮生长抑制因子(VEGI)、色素上皮衍生因子(PEDF)、胎盘生长因子(PIGF)、血管内皮生长因子(VEGF)水平，随访期间并发症的发生情况。

结果 治疗后，B组与A组临床总有效率比较结果显示前者更高；两组最佳视力矫正、血清VEGI、PEDF水平均较治疗前升高，前者较后者更高，黄斑中心区厚度、中央视网膜厚度、血清PIGF、VEGF水平均较治疗前降低，前者较后者更低；比较B组、A组随访期间并发症总发生率后得出，前者较后者显著更低(均P <0.05)。

结论 增殖型糖尿病视网膜病变患者应用康柏西普联合微创玻璃体切割术治疗可显著改善其视功能，调节疾病相关因子，减少术后并发症的发生，临床疗效显著，安全性较高。

【关键词】增殖型糖尿病视网膜病变; 康柏西普; 微创玻璃体切割术; 视功能; 疾病相关因子【中图分类号】R774.1【文献标识码】A【基金项目】2022年河南省职业教育和继续教育精品在线开放课程项目(2022YB0638) DOI:Effects of Conbercept Combined with Minimally Invasive Vitrectomy on Visual Function and Levels of Disease-related Factors in Patients with Proliferative Diabetic Retinopathy*ZAN Xiao-ning *, SHANG Li-xiao, LI Yan.Department of ophthalmology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471000, Henan Province, ChinaAbstract: Objective To investigate the changes of visual function and disease-related factors in patients with proliferative diabetic retinopathy who neededto undergo vitrectomy combined with Conbercept. Methods A total of 98 patients with proliferative diabetic retinopathy admitted to the first affiliated hospital of Henan University of Science and Technology from October 2020 to December 2022 were selected for this study, the patients were divided into two groups according to the random number table: the group A treated with micro-invasive vitrectomy and the group B treated with micro-invasive vitrectomy combined with conbercept injection, there were 49 cases with 98 eyes. Both groups were followed up for 3 months. The clinical efficacy after treatment, visual function, serum levels of vascular endothelial growth inhibitory factor (VEGI), pigment epithalium-derived factor (PEDF), placental growth factor (PIGF) and vascular endothelial growth factor (VEGF) before and after treatment, and the occurrence of complications during follow-up were compared between the two groups. Results After treatment, the total effective rate of the group B was higher than that of the group A. After treatment, the best visual acuity correction, serum VEGI and PEDF levels of the group B and the group A were higher than before treatment, and the former was higher than the latter . Macular central area thickness, central retina thickness, serum PIGF and VEGF levels were lower than before treatment, and the former was lower than the latter . The total incidence of complications of the group B was significantly lower than and the group A during the follow-up period(all P <0.05). Conclusion The treatment of patients with proliferative diabetic retinopathy with Conbercept combined with minimally invasive vitrectomy can significantly improve their visual function, regulate disease-related factors, reduce the occurrence of postoperative complications, with significant clinical efficacy and high safety.Keywords: Proliferative Diabetic Retinopathy; Conbercept; Minimally Invasive Vitrectomy; Visual Function; Disease-related Factor 增殖型糖尿病视网膜病变是临床中较为常见的一类糖尿病微血管病变，若患者发病后未能及时接受治疗则可引起其出现视力障碍，严重可致失明，此后果危险程度相对较高[1]。